Jon Roffey PhD

Jon, a medicinal chemist by training, has more than 20 years drug discovery and commercial exploitation experience gained in the biotech and academic sectors. He has worked in therapeutic areas covering CNS, obesity, Parkinson’s disease and cancer therapies, directly contributing to the development of multiple candidate drugs and late stage clinical agents. In 2015 Jon joined CRUK Commercial Partnerships (previously CRT) most recently establishing CRUK’s largest drug discovery alliance, a major 5-year alliance with Celgene, to develop mRNA translation therapeutics.

He also played a major role in the formation of Azeria Therapeutics, where he is head of drug discovery with responsibility for all pre-clinical drug discovery operations. Jon was also involved in the development and commercialization of CRT’s CDK11 antibody drug conjugate platform technology, recently licensed to Glythera where he also a member of their scientific advisory board. Prior to CRUK Commercial Partnerships Jon was a senior group leader at CRT Discovery Laboratories in the oncology setting against targets including FOXA1, CDC7 and aPKC providing project leadership from target validation through to preclinical candidate nomination.